Novo Nordisk: UBS confirms buy rating

(CercleFinance.com) - UBS maintains its buy rating on the Novo Nordisk stock, with an unchanged target price of 750 DKK - representing 19% upside potential for the pharmaceutical company's shares.


As expected, Wegovy's start-up doses, newly marketed in the US, continue to be disrupted by the holiday season. We expect growth to pick up in the coming weeks, UBS says.

Novo remains the most exciting growth story in the EU pharma industry, and is now fairly valued, the broker says.


Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.